Blonanserin

Blonanserin (AD-5423) is a potent?and orally active 5-HT_2A?(K_i=0.812 nM) and?dopamine D2?receptor?(K_i =0.142?nM)?antagonist. Blonanserin is usually acts as an atypical antipsychotic?agent and can be used for the research of extrapyramidal symptoms, excessive?sedation, or?hypotension^[1]. In Vitro: Blonanserin exerts some blockade of?α1-adrenergic receptors?(K_i=26.7?nM) and also shows significant affinity for the?D3?receptor?(K_i=0.494 nM). Blonanserin possesses low affinity for the?sigma receptor?(IC₅₀=286 nM), but lacks significant?affinity?for numerous other sites including the?5-HT1A,?5-HT3,?D1,?α2-adrenergic,?β-adrenergic,?H1, and?mACh receptors?and the?monoamine transporters^[1].
In Vivo: Blonanserin (oral gavage; 1 mg/kg; 14 days) significantly ameliorates the social deficit observed in PCP-administered mice and inhibits the decrease in the levels of Ser897-phosphorylation, but preatment with blonanserin does not affect the social behaviors in saline-administered mice^[2].